CFO
TEVA icon

CVA Family Office’s Teva Pharmaceuticals TEVA Stock Holding History

CVA Family Office’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-94
Closed -$1K – 923
2021
Q3 		$1K Hold
94
– – ﹤0.01% 355
2021
Q2 		$1K Hold
94
– – ﹤0.01% 930
2021
Q1 		$1K Hold
94
– – ﹤0.01% 762
2020
Q4 		$1K Hold
94
– – ﹤0.01% 349
2020
Q3 		$1K Hold
94
– – ﹤0.01% 355
2020
Q2 		$1K Hold
94
– – ﹤0.01% 317
2020
Q1 		$1K Buy
+94
New +$963 ﹤0.01% 302

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CVA Family Office's TEVA Position: Q4 2021 in Review

CVA Family Office sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 94 shares — an estimated $1K sold.

CVA Family Office first reported a position in TEVA in Q1 2020 and held it in 7 quarters. The position peaked at $1K in Q3 2021. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • CVA Family Office reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • CVA Family Office sold 94 Teva Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • CVA Family Office first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • CVA Family Office's Teva Pharmaceuticals position peaked at $1K in Q3 2021.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on CVA Family Office's 13F filing for Q4 2021, filed 25 Jan 2022.